Ceftibuten
From Wikipedia, the free encyclopedia
 |
|
|
Ceftibuten
|
|
| Systematic (IUPAC) name | |
| (6R,7R)-7-([(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino) -8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C15H14N4O6S2 |
| Mol. mass | 410.427 g.mol-1 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent, with 2 dosage forms, capsule or oral suspension. It is marketed by Shionogi USA under the trade name Cedax
Contents |
[edit] Clinical use
[edit] Indications
Ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
[edit] Formulations
Ceftibuten is available as capsules containing 400 mg, and a powder for oral suspension containing 90 mg per 5 ml.
[edit] See also
[edit] External links
|
||||||||||||||||||||
